As the industry leader in developing next generation antibody-drug conjugates (ADCs), our technology sets a new standard. Our robust pipeline of antibody-based therapies is designed to address significant, unmet medical needs in the community.
OUr adc: her2
Breast cancer is the leading cause of death for woman in the United States. HER2 targeting cancer therapy has been proven to be effective for HER2 expressing breast and gastric cancers. Increasing evidence has shown that many other types of cancers also express HER2 at high levels. Annual sale of HER2 targeting cancer therapy (Herceptin, Perjeta, and Kadcyla) is about $5 billion and growing.
We have developed an anti-HER2 ADC (ZV203) that is more efficacious than Kadcyla in xenograft and patient-derived xenograft (PDX) studies and demonstrates lower toxicity in preclinical evaluations. Combination of ZV203 with the current, standard breast cancer therapy, Herceptin, shows additional effect on HER2 overexpressing cancers. ZV203 is scheduled to enter into clinical trials for gastric and breast cancer in Q1, 2017.
our adc: c-met
The receptor tyrosine kinase, c-Met, is not only involved in cell proliferation, invasion, and angiogenesis, but also is aberrantly expressed in a variety of cancers. In addition, autocrine expression of the hepatocyte growth factor (HGF), the only known ligand for the c-Met receptor, is also found in many cancers driven by the c-Met receptor. Elevated c-Met levels have also been shown to be a resistant mechanism for other therapies such as EGFR inhibition. Although c-Met is accepted as an attractive anti-cancer target, the development of cancer therapy targeting c-Met receptor remains challenging. Clinical development of c-Met/HGF targeting antibodies displayed initial evidence of clinical efficacy but failed in Phase III. Small molecule inhibitors often suffer from selectivity issues. Antibody-drug conjugates, which combines an antibody with highly potent cytotoxic agents, become an attractive approach against c-Met overexpressing cancers such non-small cell lung cancer (NSCLC). We have identified an anti-c-Met antibody STI-0602 from our internal antibody library G-MAB and generated ADCs from a panel of our unique cytotoxic agents. Anti-c-Met ADCs showed dramatic anti-tumor activities on a variety of NSCLC xenograft models. The program is currently in preclinical development and plan to file IND by Q2 2017.